GLIMEPIRIDE (glimepiride) by Signatur Biosciences is cells. Approved for type 2 diabetes mellitus ( ), type 1 diabetes mellitus, type 2 diabetes mellitus. First approved in 2005.
Drug data last refreshed 19h ago
cells. Sulfonylureas bind to the sulfonylurea receptor in the pancreatic beta-cell plasma membrane, leading to closure of the ATP-sensitive potassium channel, thereby stimulating the release of insulin.
Worked on GLIMEPIRIDE at Signatur Biosciences? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Evaluate the Efficacy and Safety of Empagliflozin or Glimepiride Combination Therapy in Type 2 Diabetes Mellitus Patients
Efficacy and Safety of Sotagliflozin Versus Glimepiride and Placebo in Participants With Type 2 Diabetes Mellitus That Are Taking Metformin Monotherapy
The Effects of Glimepiride in Patients With Type 2 Diabetes and Chronic Heart Failure
Teneligliptin-Glimepiride DDI Study
Pharmacokinetic/Pharmacodynamic Drug-drug Interaction of Evogliptin 5mg and Glimepiride 4mg